EC approves BMS's daclatasvir for HCV

The European Commission approved Daklinza daclatasvir ( BMS-790052) from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with other therapies to treat HCV genotypes 1, 2, 3 and 4.

BMS said the selective HCV NS5A protein inhibitor's label recommends multiple regimens, including treatment of genotypes 1 and 4 with or without compensated cirrhosis in combination with Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD); HCV genotype 3 with compensated cirrhosis or previous HCV treatment in combination with Sovaldi and ribavirin; and HCV genotype 4 in combination with ribavirin and peginterferon alfa. ...